Cancer Family
Central Nervous System Embryonal Tumor
CI-CAN-00000115Explore in graph →
Loading cancer entity…
Cancer Family
CI-CAN-00000115Explore in graph →
Variants & evidence
46 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ASCL1 EXPRESSION1 | ||||||||
| (prognostic) | Atypical Teratoid/Rhabdoid Tumor | Prognostic | B | Supports Better Outcome | 5 | submitted | EID7055This retrospective study analyzed the role of ASCL1 expression in the overall prognosis of patients with atypical teratoid rhabdoid tumors. ASCL1 expression was found to correlate with superior 5-year… (full text at CIViC) PMID 25882982 · Torchia et al., 2015 · Open in CIViC | civic |
| BCOR ITD4 | ||||||||
| (diagnostic) | Central Nervous System Tumor with BCOR Internal Tandem Duplication | Diagnostic | B | Supports Positive | 4 | accepted | EID10800The authors generated genome-wide DNA methylation profiles of 323 tumors with an institutional diagnosis of ‘primitive neuroectodermal tumors of the central nervous system (CNS-PNETs)’, which are hi… (full text at CIViC) PMID 26919435 · Sturm et al., 2016 · Open in CIViC | civic |
| (oncogenic) | Central Nervous System Tumor with BCOR Internal Tandem Duplication | Oncogenic | B | Supports Oncogenicity | 4 | accepted | EID1080410/323 studied high-grade primitive neuroectodermal tumors of the central nervous system (CNS-HGPNETs) clustered together based on their unique methylation profile. 10/10 of those tumors exhibited in… (full text at CIViC) PMID 26919435 · Sturm et al., 2016 · Open in CIViC | civic |
| (diagnostic) | Central Nervous System Tumor with BCOR Internal Tandem Duplication | Diagnostic | B | |||||
| BRD4 Overexpression1 | ||||||||
| JQ1 | Childhood Medulloblastoma | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID9316Predominantly high-level expression of BRD4 was found in the majority of medulloblastoma cell lines examined (HD-MB3, ONS-76, UW-228, D-341, and D-283); the exception being the Daoy cell line exhibiti… (full text at CIViC) PMID 24231268 · Henssen et al., 2013 · Open in CIViC | civic |
| Amplification1 | ||||||||
| (diagnostic) | Embryonal Tumor with Multilayered Rosettes, C19MC-Altered | Diagnostic | A | Supports Positive | 5 | accepted | EID12389This landmark study contributed to the recognition of embryonal tumor with multilayered rosettes (ETMRs) as a distinct entity in the 2016 WHO classification. Previously, ETMRs were included within the… (full text at CIViC) PMID 19962671 · Li et al., 2009 · Open in CIViC | civic |
| TTYH1::C19MC fusion1 | ||||||||
| (diagnostic) | Embryonal Tumor with Multilayered Rosettes | Diagnostic | A | Supports Positive | 5 | accepted | EID12390This study aimed to identify the mechanism underlying overexpression of a miRNA cluster on chromosome 19q13.4 (C19MC) and its oncogenicity in embryonal tumors with multilayered rosettes (ETMRs). Throu… (full text at CIViC) PMID 24316981 · Kleinman et al., 2014 · Open in CIViC | civic |
| v::C19MC fusion1 | ||||||||
| (diagnostic) | Embryonal Tumor with Multilayered Rosettes | Diagnostic | A | Supports Positive | 5 | accepted | EID12391This cohort study examined the molecular landscape of embryonal tumors with multilayered rosettes (ETMRs) at diagnosis and relapse. ETMRs have previously been shown to frequently (~90%) exhibit amplif… (full text at CIViC) PMID 31802000 · Lambo et al., 2019 · Open in CIViC | civic |
| CTNNB1 D32Y1 | ||||||||
| (prognostic) | Medulloblastoma, WNT-Activated | Prognostic | C | Supports Better Outcome | 3 | submitted | EID9017A retrospective study evaluated 72 pediatric medulloblastoma patients for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-cateni… (full text at CIViC) PMID 19197950 · Fattet et al., 2009 · Open in CIViC | civic |
| CTNNB1 Exon 3 Mutation4 | ||||||||
| (prognostic) | MedulloblastomaCURATED_BROADER | Prognostic | B | Supports Better Outcome | 4 | submitted | EID7966In a study of 109 pediatric medulloblastomas, children with medulloblastomas that showed a nucleopositive beta-catenin immunophenotype (27 of 109; 25%) had significantly better overall (OS) and event-… (full text at CIViC) PMID 16258095 · Ellison et al., 2005 · Open in CIViC | civic |
| (diagnostic) | Childhood Medulloblastoma | Diagnostic | B | Supports Positive | 4 | accepted | EID7967A total of 51 medulloblastomas from two independent cohorts (19 and 32 cases) were assessed for evidence of Wnt/Wg pathway activation, alongside a genome-wide analysis of associated copy-number aberra… (full text at CIViC) PMID 17172831 · Clifford et al., 2006 · Open in CIViC | civic |
| (prognostic) | Childhood Medulloblastoma | Prognostic | B | Supports | ||||
| CTNNB1 G34R1 | ||||||||
| (prognostic) | Childhood Medulloblastoma | Prognostic | C | Supports Better Outcome | 3 | submitted | EID9014A retrospective study evaluated 72 pediatric medulloblastoma patients for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-cateni… (full text at CIViC) PMID 19197950 · Fattet et al., 2009 · Open in CIViC | civic |
| CTNNB1 I35K1 | ||||||||
| (prognostic) | Childhood Medulloblastoma | Prognostic | C | Supports Better Outcome | 3 | submitted | EID9016A retrospective study evaluated 72 pediatric medulloblastoma patients for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-cateni… (full text at CIViC) PMID 19197950 · Fattet et al., 2009 · Open in CIViC | civic |
| CTNNB1 S33F1 | ||||||||
| (prognostic) | Childhood Medulloblastoma | Prognostic | C | Supports Better Outcome | 4 | submitted | EID9015A retrospective study evaluated 72 pediatric medulloblastoma patients for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-cateni… (full text at CIViC) PMID 19197950 · Fattet et al., 2009 · Open in CIViC | civic |
| H3-3A G35R1 | ||||||||
| (diagnostic) | Central Nervous System Embryonal TumorCURATED_BROADER | Diagnostic | B | Supports Positive | 3 | rejected | EID9821Korshunov, et al. (2016) studied 81 central nervous system tumors (located in temporal and parietal lobe in 80% of cases, 88% carried TP53 variant, 95% carried ATRX loss), including: 59 glioblastoma-l… (full text at CIViC) PMID 26482474 · Korshunov et al., 2016 · Open in CIViC | civic |
| H3-3A G35V1 | ||||||||
| (diagnostic) | Central Nervous System Embryonal TumorCURATED_BROADER | Diagnostic | C | Supports Positive | 1 | submitted | EID9823Korshunov, et al. (2016) studied 81 central nervous system tumors (located in temporal and parietal lobe in 80% of cases, 88% carried TP53 variant, 95% carried ATRX loss), including: 59 glioblastoma-l… (full text at CIViC) PMID 26482474 · Korshunov et al., 2016 · Open in CIViC | civic |
| MYC Amplification1 | ||||||||
| (prognostic) | MedulloblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 5 | submitted | EID7048Group 3 medulloblastomas with MYC amplifications are often associated with large cell/anaplastic histology, young patients, and overall poor prognosis. PMID 15328187 · Lamont et al., 2004 · Open in CIViC | civic |
| MYCN Amplification2 | ||||||||
| Arsenic Trioxide | MedulloblastomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID5327In a patient derived xenograft from a sonic hedgehog driven medulloblastoma patient, MYCN amplification conferred to resistance to SMO inhibition with Sonidegib. This PDX was shown to be responsive t… (full text at CIViC) PMID 23291299 · Kim et al., 2013 · Open in CIViC | civic |
| Sonidegib | MedulloblastomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID5325In a sonic hedgehog driven medulloblastoma patient derived xenograft harbouring a MYCN amplification, SMO inhibitor Sonidegib did not have an effect on cell proliferation. PMID 24651015 · Kool et al., 2014 · Open in CIViC | civic |
| NTRK3 EXPRESSION1 | ||||||||
| (prognostic) | MedulloblastomaCURATED_BROADER | Prognostic | B | Supports Positive | 3 | submitted | EID1968Patients with tumors expressing high levels of trkC mRNA had significantly longer intervals without disease progression than those with low levels (log-rank, P = 0.03) and a more favorable overall sur… (full text at CIViC) PMID 7809137 · Segal et al., 1994 · Open in CIViC | civic |
| NTRK3 Fusion1 | ||||||||
| Entrectinib | Desmoplastic/Nodular Medulloblastoma | Predictive | C | Does Not Support Sensitivity Response | 2 | submitted | EID12608In the STARTRK-NG Phase 1/2 trial of entrectinib in pediatric patients, with extracranial solid tumors or primary CNS tumors, aged <22 years with relapsed or refractory disease, tumors with fusions… (full text at CIViC) PMID 35395680 · Desai et al., 2022 · Open in CIViC | civic |
| PTCH1 Deletion1 | ||||||||
| Sonidegib | MedulloblastomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID5326In a sonic hedghehog driven medulloblastoma patient derived xenograft harbouring a PTCH1 deletion, SMO inhibition with Sonidegib showed inhibition of proliferation. PMID 24651015 · Kool et al., 2014 · Open in CIViC | civic |
| PTCH1 LOH1 | ||||||||
| Vismodegib | MedulloblastomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID749Loss-of-heterozygosity in SHH-driven medulloblastoma was associated with increased PFS under therapy with vismodegib (AKA HhAntag691, GDC0449, GDC-0449). 43 patients total were enrolled for this study… (full text at CIViC) PMID 26169613 · Robinson et al., 2015 · Open in CIViC | civic |
| PTCH1 Mutation1 | ||||||||
| Sonidegib | MedulloblastomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID748133 sonic-hedghog driven medulloblastomas were sequenced for alterations (WGS or WES). 60 cases exhibited PTCH1 mutations, most of which were likely loss-of-function (spread across the gene and of typ… (full text at CIViC) PMID 24651015 · Kool et al., 2014 · Open in CIViC | civic |
| SMARCA4 Loss1 | ||||||||
| (diagnostic) | Atypical Teratoid/Rhabdoid Tumor | Diagnostic | A | Supports Positive | 5 | submitted | EID8864Atypical teratoid/rhabdoid tumor (AT/RT) is now defined by WHO guidelines by alterations of either INI1 (SMARCB1) or BRG1 (SMARCA4; rarely mutated) which result in loss of tumor nuclear expression of … (full text at CIViC) PMID 27157931 · Louis et al., 2016 · Open in CIViC | civic |
| SMARCB1 Deletion + SMARCB1 Single nucleotide variant1 | ||||||||
| (diagnostic) | Atypical Teratoid/Rhabdoid Tumor | Diagnostic | B | Supports Positive | 4 | submitted | EID11177325 ATRTs underwent methylation profiling, revealing three methylation distinct clusters - ATRT-TYR, ATRT-SHH and ATRT-MYC. In the ATRT-TYR subgroup, the characteristic pattern of SMARCB1 loss was of … (full text at CIViC) PMID 31889194 · Ho et al., 2020 · Open in CIViC | civic |
| SMARCB1 Loss3 | ||||||||
| (diagnostic) | Atypical Teratoid/Rhabdoid Tumor | Diagnostic | A | Supports Positive | 5 | submitted | EID8863Atypical teratoid/rhabdoid tumor (AT/RT) is now defined by WHO guidelines by alterations of either INI1 (SMARCB1) or BRG1 (SMARCA4; rarely mutated) which result in loss of tumor nuclear expression of … (full text at CIViC) PMID 27157931 · Louis et al., 2016 · Open in CIViC | civic |
| 〃 | Atypical Teratoid/Rhabdoid Tumor | Diagnostic | B | Supports Positive | 4 | accepted | EID886253 pediatric tumors consisting of 20 AT/RT, 10 PNET, and 23 other central nervous system tumors were classified using microscopic diagnosis, and then tested for expression of the SMARCB1 gene product … (full text at CIViC) PMID 15105654 · Judkins et al., 2004 · Open in CIViC | civic |
| Tazemetostat | Atypical Teratoid/Rhabdoid Tumor | Predictive | B | Supports Sensitivity Response | ||||
| SMARCB1 LOSS OF NUCLEAR PROTEIN EXPRESSION3 | ||||||||
| (diagnostic) | Cribriform Neuroepithelial Tumor | Diagnostic | C | Supports Positive | 4 | accepted | EID12332This study compared cribriform neuroepithelial tumor (CRINET) and atypical teratoid/rhabdoid tumor (AT/RT) to determine whether CRINET is a distinct entity or a variant of AT/RT. The study contained 1… (full text at CIViC) PMID 27380723 · Johann et al., 2017 · Open in CIViC | civic |
| 〃 | Cribriform Neuroepithelial Tumor | Diagnostic | C | Supports Positive | 3 | accepted | EID12327This is the first case report of cribriform neuroepithelial tumor (CRINET), a rare brain cancer identified in a 26-month-old girl and a 10-month-old boy, affecting the third and fourth ventricles. His… (full text at CIViC) PMID 19915490 · Hasselblatt et al., 2009 · Open in CIViC | civic |
| 〃 | Cribriform Neuroepithelial Tumor | Diagnostic | C | Supports | ||||
| SMO D473H3 | ||||||||
| Patidegib | MedulloblastomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1099Saridegib treatment induced tumor reduction and significantly prolonged survival in a Shh-driven mouse medulloblastoma model, and was found to be active in cells with the D473H point mutation. PMID 22550175 · Lee et al., 2012 · Open in CIViC | civic |
| Vismodegib | MedulloblastomaCURATED_BROADER | Predictive | C | Supports Resistance | 3 | accepted | EID745In this case report, the D473H mutation was reported as an acquired mechanism of resistance to the hedgehog pathway inhibitor GDC-0449 (vismodegib). PMID 19726788 · Yauch et al., 2009 · Open in CIViC | civic |
| 〃 | MedulloblastomaCURATED_BROADER | Predictive | D | |||||
| SNCAIP Tandem duplication1 | ||||||||
| (diagnostic) | Medulloblastoma, Non-WNT/Non-SHH, Group 4 | Diagnostic | B | Supports Positive | 3 | submitted | EID11193Analysis of somatic copy number alterations (SCNAs) in 1087 medulloblastoma tumours identified a recurrent tandem duplication of SNCAIP that was restricted to Group 4 medulloblastoma. SNCAIP duplicati… (full text at CIViC) PMID 22832581 · Northcott et al., 2012 · Open in CIViC | civic |
| SUFU Deletion1 | ||||||||
| Sonidegib | MedulloblastomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID5324In a sonic hedgehog driven medulloblastoma patient derived xenograft harbouring a SUFU deletion, SMO inhibition with LDE225 (Sonidegib) did not affect cell proliferation. PMID 24651015 · Kool et al., 2014 · Open in CIViC | civic |
| TP53 Mutation6 | ||||||||
| (predisposing) | Medulloblastoma, SHH-Activated, TP53-MutantALIAS | Predisposing | B | Supports Predisposition | 5 | submitted | EID8346This international, multicenter study analyzed patients with medulloblastoma (MB) from both retrospective and prospective cohorts in order to identify consensus MB predisposition genes. A total of 102… (full text at CIViC) PMID 29753700 · Waszak et al., 2018 · Open in CIViC | civic |
| (prognostic) | Medulloblastoma, SHH-Activated | Prognostic | B | Supports Poor Outcome | 5 | accepted | EID8347In the childhood (≥4.3 years) SHH-MB subgroup, TP53 mutations (n=13) are associated with shorter progression-free survival (PFS) compared to the no mutation group (n=35) (HR, 3.47; 95% CI, 1.29 to 9.3… (full text at CIViC) PMID 28545823 · Schwalbe et al., 2017 · Open in CIViC | civic |
| 〃 | MedulloblastomaCURATED_BROADER | Prognostic | ||||||
Data updated 2 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| Supports Positive |
| 3 |
| accepted |
EID1088710 cases of high-grade neuroepithelial tumor (HGNET) with BCOR exon 15 ITD were studied. In addition, 25 previously reported and published patients were included in survival analyses. These tumors ar… (full text at CIViC) PMID 31104347 · Ferris et al., 2020 · Open in CIViC |
| civic |
| 〃 | Central Nervous System Tumor with BCOR Internal Tandem Duplication | Diagnostic | B | Supports Positive | 3 | accepted | EID11581Six cases of CNS high-grade neuroepithelial tumor (HGNET) with BCOR exon 15 internal tandem duplication (ITD) were studied. The authors analyzed their clinical, pathologic and molecular characteristic… (full text at CIViC) PMID 29226988 · Yoshida et al., 2018 · Open in CIViC | civic |
| 4 |
| submitted |
EID9013This retrospective study evaluated 72 pediatric medulloblastoma patients for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-cat… (full text at CIViC) PMID 19197950 · Fattet et al., 2009 · Open in CIViC |
| civic |
| (diagnostic) | Childhood Medulloblastoma | Diagnostic | B | Supports Positive | 3 | accepted | EID7965A series of 72 pediatric medulloblastomas were evaluated for CTNNB1 mutations (by direct sequencing), copy number alterations (by array-comparative genomic hybridization), and beta-catenin protein exp… (full text at CIViC) PMID 19197950 · Fattet et al., 2009 · Open in CIViC | civic |
| 3 |
| submitted |
EID11180In the dose expansion of phase I pediatric trial (NCT02601937) of the EZH2 inhibitor tazemetostat, the overall response in 21 patients with SMARCB1-deficient atypical teratoid rhabdoid tumors (ATRT) w… (full text at CIViC) |
| civic |
| 3 |
| accepted |
EID12328This study explored the molecular features of cribriform neuroepithelial tumors (CRINET) using multiplex ligation-dependent probe amplification (MLPA) and molecular inversion profiling (MIP) assays al… (full text at CIViC) PMID 26352987 · Gessi et al., 2015 · Open in CIViC |
| civic |
| — |
| submitted |
EID4427In an in vitro study, a C3H10T1/2 cell line expressing SMO D473H mutation, demonstrated resistance to vismodegib treatment (IC50: 3,000,000 nmol/L vs. 20 nmol/L) compared to C3H10T1/2 cells expressing… (full text at CIViC) PMID 21123452 · Dijkgraaf et al., 2011 · Open in CIViC |
| civic |
| B |
| Supports Poor Outcome |
| 4 |
| submitted |
EID7963This study showed that patients with TP53 mutated medulloblastoma (8/49, 16%) exhibited worse prognosis compared to those with wildtype medulloblastoma (41/49, 84%). A 5-year overall survival of 0% wa… (full text at CIViC) PMID 20142599 · Tabori et al., 2010 · Open in CIViC |
| civic |
| 〃 | MedulloblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID7964This study examined the prognostic implication of TP53 mutation status in different molecular subgroups of medulloblastoma. A discovery cohort of 397 patients and a validation cohort of 156 cases were… (full text at CIViC) PMID 23835706 · Zhukova et al., 2013 · Open in CIViC | civic |
| (diagnostic) | Medulloblastoma, SHH-Activated, TP53-MutantALIAS | Diagnostic | B | Supports Positive | 4 | submitted | EID8345One of the goals of this study is to understand the biology of the sonic-hedgehog subgroup of medulloblastoma (SHH-MB) across different age groups. A large cohort of patients (n=133) with SHH-MB, incl… (full text at CIViC) PMID 24651015 · Kool et al., 2014 · Open in CIViC | civic |
| Vismodegib | Medulloblastoma, SHH-Activated, TP53-MutantALIAS | Predictive | C | Does Not Support Sensitivity Response | 3 | submitted | EID8348Two phase II studies (PBTC-025B, n=31, age ≥ 22 years; PBTC-032, n=12, age 3-21 years) assessed the targeted efficacy of vismodegib, an SMO inhibitor, in patients with recurrent sonic hedgehog subgrou… (full text at CIViC) PMID 26169613 · Robinson et al., 2015 · Open in CIViC | civic |